Want to see HK:2252 full AI Analyst Report?
Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$25.00
▼(-26.77% Downside)
Action:Upgraded
Date:06/18/26
The score is held down primarily by weak financial performance: despite strong 2025 revenue growth and improving losses, profitability is still deeply negative and cash flow remains in the red. Technicals also weigh on the score with a price below major moving averages and negative MACD, even though momentum appears oversold. Valuation contributes only modestly because the negative P/E reflects losses and there is no dividend yield support.
Positive Factors
Revenue Growth
A ~61% revenue acceleration in 2025 signals durable commercial traction for surgical-robotics platforms. Sustained top-line expansion supports scale advantages, improves per-unit absorption of fixed R&D and SG&A, and creates a clearer path to operating leverage as adoption broadens across hospitals.
Negative Factors
Sustained Unprofitability
Deep net losses (net margin ~-45%) and severely negative ROE (~-59%) indicate the business is not yet generating shareholder returns. Persistent unprofitability erodes equity, hampers reinvestment capacity, and makes achieving self-sustaining growth contingent on substantial margin improvement or ongoing external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A ~61% revenue acceleration in 2025 signals durable commercial traction for surgical-robotics platforms. Sustained top-line expansion supports scale advantages, improves per-unit absorption of fixed R&D and SG&A, and creates a clearer path to operating leverage as adoption broadens across hospitals.
Read all positive factors
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.10B
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue Growth114.97%
EPS Growth63.21%
CountryHK
Employees464
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.16Price Target Upside14.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$1.14B
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toum...
How the Company Makes Money
null...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
45
Neutral
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 551.07M | 257.25M | 104.59M | 21.60M | 2.15M |
| Gross Profit | 266.62M | 86.22M | 14.69M | 6.56M | 919.00K |
| EBITDA | -96.84M | -413.34M | -893.36M | -1.05B | -543.84M |
| Net Income | -249.66M | -642.41M | -1.01B | -1.14B | -582.92M |
Balance Sheet | |||||
| Total Assets | 1.34B | 1.28B | 1.43B | 1.93B | 2.79B |
| Cash, Cash Equivalents and Short-Term Investments | 640.42M | 612.23M | 507.71M | 747.96M | 1.94B |
| Total Debt | 426.37M | 691.33M | 560.42M | 219.95M | 204.68M |
| Total Liabilities | 935.07M | 1.02B | 926.15M | 522.25M | 401.73M |
| Stockholders Equity | 410.85M | 278.20M | 519.48M | 1.42B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | -38.83M | -340.21M | -634.30M | -1.09B | -674.47M |
| Operating Cash Flow | -36.30M | -298.12M | -567.84M | -898.48M | -540.49M |
| Investing Cash Flow | 2.55M | -47.60M | -58.38M | -267.82M | -396.57M |
| Financing Cash Flow | 66.32M | 449.96M | 385.68M | -27.95M | 1.39B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Negative
34.14
Price Trends
25.38
Negative
26.55
Negative
26.15
Negative
Market Momentum
-0.11
Negative
49.50
Neutral
28.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Negative. The current price of 34.14 is above the 20-day moving average (MA) of 23.91, above the 50-day MA of 25.38, and above the 200-day MA of 26.15, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 49.50 is Neutral, neither overbought nor oversold. The STOCH value of 28.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2252.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.72B | 17.25 | 12.01% | 1.26% | 10.19% | 23.70% | |
65 Neutral | HK$5.41B | 24.91 | 10.38% | 1.50% | 3.83% | -27.04% | |
59 Neutral | HK$2.97B | 56.85 | 2.07% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$13.65B | 36.62 | 6.07% | ― | -3.62% | ― | |
43 Neutral | HK$25.10B | -87.12 | -52.78% | ― | 114.97% | 63.21% | |
40 Underperform | HK$1.48B | -0.78 | -7.01% | ― | ― | ― |
* Healthcare Sector Average
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
24.20
5.84
31.81%
HK:0853
MicroPort Scientific
7.12
-2.10
-22.78%
HK:1789
AK Medical Holdings Ltd.
5.99
0.16
2.66%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.16
-4.79
-80.50%
HK:2172
MicroPort NeuroTech Limited
9.25
-3.97
-30.04%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.06
0.45
6.81%
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
MicroPort MedBot’s Toumai Surgical Robot Tops 200 Global Installations
Jun 26, 2026
Shanghai MicroPort MedBot said its flagship Toumai Laparoscopic Surgical Robot has surpassed 200 commercial installations worldwide, following more than 300 global orders, with all deployed systems accepted by end customers. The system now ranks f...
MicroPort MedBot Wins Landmark EU CE Mark for Toumai Remote Surgical Robot
Jun 21, 2026
Shanghai MicroPort MedBot announced that its self-developed Full-department Application of Toumai Laparoscopic Surgery Robot for Remote Surgery, known as Toumai Remote, has obtained the EU CE Mark, becoming the first remote surgical robot to recei...
MicroPort MedBot’s Toumai Surgical Robot Surpasses 300 Global Orders as Remote Surgery Push Accelerates
Jun 16, 2026
Shanghai MicroPort MedBot reported that cumulative orders for its core surgical robot portfolio have reached nearly 400 units, including more than 300 commercial orders worldwide for its Toumai laparoscopic system, with new orders in the first hal...
Shanghai MicroPort MedBot Wins Shareholder Backing for Profit Plan and Capital Mandates
Jun 5, 2026
Shanghai MicroPort MedBot held its 2025 annual general meeting in Shanghai, with shareholders representing about 55.54% of issued shares in attendance. All resolutions were approved, including the 2025 annual report, supervisory committee report a...
MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans
May 14, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. plans to adopt a new share scheme that will allow the company to grant new and existing shares, as well as options over new shares, to eligible participants as incentives for their contributions or poten...
MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table
May 14, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has called its annual general meeting for 5 June 2026 in Shanghai, where shareholders will review the 2025 annual report, supervisory committee report and proposed profit distribution plan, as well as vo...
MicroPort MedBot Completes Near-Full H Share Circulation to Boost Liquidity
Apr 23, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd., a Hong Kong-listed Chinese medical technology company specializing in robotic-assisted surgical systems, continues to refine its capital structure to support its growth in domestic and global healthcare...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.